Is there enough benefit to justify sequencing all patients’ tumors? No.
Patients often come to the oncology clinic with questions about alternative anticancer therapies ranging from cannabis oil to vitamin C infusions purported to provide remarkable results. Proponents highlight a hypothesis of anticancer efficacy typically corroborated by preclinical studies and selected anecdotal cases of patients who have done exceptionally well. When asked about these zealously promoted but insufficiently studied approaches, evidence-based oncologists rightly emphasize the absence of properly conducted prospective trials proving that such cases are not merely outliers but are generalizable to defined populations.
West H. No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data. JAMA Oncol. 2016;2(6):717–718. doi:10.1001/jamaoncol.2016.0075
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: